Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational <i>psoriasis study of health outcomes</i> (<scp>PSoHO</scp>)
Andreas Pinter(Goethe University Frankfurt), C. Paul(Université Fédérale de Toulouse Midi-Pyrénées), L. Puig(Universitat Autònoma de Barcelona), Catherine Reed(Eli Lilly (United States)), Alan Brnabic(Eli Lilly (United States)), Elisabeth Riedl(Eli Lilly (United States)), Tsen‐Fang Tsai(National Taiwan University Hospital), Saxon D. Smith(Australian National University), Antonio Costanzo(Humanitas University), Adam Reich(Rzeszów University of Technology), Julie Hill(Eli Lilly (United States)), Knut Schäkel(Heidelberg University), Christopher Schuster(Eli Lilly (United States)), Shirin Zaheri(Imperial College Healthcare NHS Trust), Charles Lynde(University of Toronto)
Cited by 43
Related Papers
Psoriasis Pathogenesis and Treatment
|International Journal of Molecular Sciences|2019|2k
Definition of treatment goals for moderate to severe psoriasis: a European consensus
|Archives of Dermatological Research|2010|892
Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*
|British Journal of Dermatology|2020|590
Assessment of Pruritus Intensity: Prospective Study on Validity and Reliability of the Visual Analogue Scale, Numerical Rating Scale and Verbal Rating Scale in 471 Patients with Chronic Pruritus
|Acta Dermato Venereologica|2012|579
Visual Analogue Scale: Evaluation of the Instrument for the Assessment of Pruritus
|Acta Dermato Venereologica|2012|502